Top-down mandates from authorities have a history of being flawed, from the food pyramid to the FDA's stance on opioids. True progress emerges not from command-and-control edicts but from a decentralized system that allows for thousands of experiments. Protecting the freedom for most to fail is what allows a few breakthrough ideas to succeed and benefit everyone.

After an intervention like cash transfers has been validated by over 100 randomized trials, spending more money on another study is unethical. That funding is being taken from potential beneficiaries to measure something already known, preventing more lives from being improved.

The most valuable lessons in clinical trial design come from understanding what went wrong. By analyzing the protocols of failed studies, researchers can identify hidden biases, flawed methodologies, and uncontrolled variables, learning precisely what to avoid in their own work.

The scientific gold standard of a placebo-controlled trial creates a profound ethical burden for researchers in neonatal care. To prove a drug's efficacy for widespread use, scientists must knowingly deny the potentially life-saving treatment to half of the fragile infants in a study, forcing them to carry the pain of that decision.

Despite strong observational evidence from Israel suggesting early allergen exposure was beneficial, medical guidelines didn't change. It required the "gold standard" of a randomized controlled trial (the LEAP study) to definitively prove the link and force institutions to formally reverse their harmful avoidance recommendations.

A routine knee surgery performed on millions, believed to work based on mechanistic reasoning, was found to be ineffective when tested against a placebo (sham surgery) in a randomized controlled trial. This highlights that even visually intuitive interventions can fail in complex biological systems, making rigorous testing essential.

The key public health failure during the pandemic was not initial uncertainty, but the systemic inability to execute rapid experiments. Basic, knowable questions about transmission, masks, and safe distances went unanswered because of a failure to generate data through randomized trials.

Designing a randomized trial to compare surgery versus systemic therapy alone is nearly impossible. A previous attempt, the SPARE study, failed to recruit because clinicians and patients already had strong pre-existing opinions on the best course of action, a bias that persists today.

Evidence is a critical input, but not the sole determinant of a decision. For instance, antibiotics are proven to clear infections, but a terminally ill patient may decline them based on their values. Evidence must always be combined with context, cost, and human values to reach a course of action.